Sentences with phrase «program at reduced pricing»

The company then issued an apology letter saying they had disappointed customers, and introduced a battery replacement program at reduced pricing.

So Congress grandfathered them into the program at reduced prices, believing that insurance premiums would offset rising federal disaster aid.

Not exact matches

Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tPrograms (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Walmart Canada's commitment to reducing food waste includes selling food that is nearing its best before date at a discounted price as part of a Customer Value Program.

Initiatives include the Backpack Food Program where the foundation partners with local food banks and schools to provide knapsacks filled with nutritious, easy - to - prepare, nonperishable food for students who are at risk for hunger when free or - reduced price school lunches are unavailable.

Any public school containing these grades with a minimum enrollment of 125 students per school site, have a breakfast program, and serve at least 40 % of its lunches to free and reduced price meals shall be eligible for a state financial supplement.

One significant victory in that battle was last year's passage of the Healthy, Hunger - Free Kids Act which, among other things, uses Medicaid data to directly certify children for free and reduced price meals; helps states improve the certification process for school meal aid; allows universal free meals for students in high poverty communities; and expands USDA authority to support meals served to at - risk children in after school programs.

In the last four years, 55 CPS employees have now been accused of defrauding the federal school lunch program by enrolling ineligible children for free or reduced - price lunches, a pattern of abuse that highlights problems at every level of the program, Sullivan said.

Klopfenstein and Thomas (2010) offer three significant ways in which non-AP students at a school may pay the price for the AP program: they may receive lower instructional quality, as the best teachers are siphoned off to teach AP students; they are in larger classes, as AP classes are smaller than typical high school classes; and non-AP course offerings are reduced or limited in order to fund, staff, and expand AP course offerings.

More than 30 million kids a year participate in the National School Lunch Program, getting free or reduced - price meals at school.

School nurses can help increase student nutritional intake through school breakfast participation by encouraging their school (s) to implement a breakfast after the bell program and to offer nutritious breakfasts at no cost to all students, particularly in schools or school districts with high concentrations of students certified for free and reduced - price school meals.

Participation is limited to schools in which at least 50 percent of the student population qualifies for free or reduced - price lunches through the National School Lunch Program.

This program allows us to purchase diapers at a greatly reduced price.

When I asked at a Parent Advisory Committee meeting this summer how this price increase would likely impact participation in the program, I was told that the increase affects only about 8 % of the students in our district, because the vast majority of kids here — almost 90 % — are on free / reduced lunch.

Teaming up with the Food Bank of the Southern Tier, the Rock on Café program runs a «Week of Caring» to collect food donations to support the Food Bank's BackPack Program, which provides healthy, kid - friendly, and easy - to - prepare foods to children at risk of hunger over weekends and holiday breaks when they do not have access to free or reduced price school meal prprogram runs a «Week of Caring» to collect food donations to support the Food Bank's BackPack Program, which provides healthy, kid - friendly, and easy - to - prepare foods to children at risk of hunger over weekends and holiday breaks when they do not have access to free or reduced price school meal prProgram, which provides healthy, kid - friendly, and easy - to - prepare foods to children at risk of hunger over weekends and holiday breaks when they do not have access to free or reduced price school meal programs.

They measured educational outcomes using standardized tests and looked at demographic data, including attendance and suspension; race and ethnicity; free and reduced price lunch status; and participation in gifted education, special education, or programs for English learners.

Students more likely to participate in free - and reduced - price lunch programs are among the same populations most likely to suffer from obesity and related health risks, said Janet Peckham, an economist in the Office of the Commissioner at the U.S. Food and Drug Administration and lead author of the study.

Both of the following videos are clips from our new Hypertrophy Training Program Design: The Alternate - Undulate Method 2 - DVD Set, which is on sale now at a reduced price until this Sunday, March 15th at midnight.

At Waiʻanae High School, one of the program sites, nearly 95 percent of students are people of color — 60 percent of those are Native Hawaiian — and roughly 70 percent of all students qualify for free or reduced - price lunch.

According to the «School Breakfast Scorecard,» released at a press conference here by the Food Research and Action Center, more than 4.16 million children in 47,627 schools now receive free or reduced - price breakfasts under the program.

To qualify for a scholarship, children had to be entering grades 1 through 4, live in New York City, attend a public school at the time of application, and come from families with incomes low enough to qualify for the U.S. government's free or reduced - price school - lunch program.

At least 40 % of the students a scholarship organization awards scholarships to must have qualified for the federal free or reduced - price lunch program in the final year they attended public school.

Eligible students must have a household income at 200 percent of the required level for the free or reduced - price lunch program.

If a public school has a schoolwide Title I program, which is permitted if 40 percent of its students are eligible for free or reduced - price lunch, then every student at the school — regardless of poverty level — is said to be a recipient of Title I services.

A bill that would have established a pilot program at the University of Hawaii at Hilo to allow kupuna to take classes for free or at a reduced price died.

This study is a comparative case study of ten elementary, middle, and high schools with strong arts programs and significant numbers of economically disadvantaged students (at least 50 percent of the student body qualifying for the federal free and reduced - price lunch program).

The program would provide $ 1,000 for each «gifted and talented» student who is already eligible for free or reduced - price school lunches, which means the household's annual income is at or below $ 45,510 annually for a family of four.

Programs limited to small populations, such as students eligible for the federal free and reduced - price lunch program, tend only to fill empty seats at existing private schools but don't do much to encourage innovation or even the expansion of existing options.

Nathaniel Hutchings is the principal at Arrowhead Elementary, one of the district's eight Title I schools that serves a predominantly low - socioeconomic student population with some 60 percent currently qualifying for free / reduced - price lunch programs.

Renaissance Charter School at Pines will participate in the National School Lunch Program and free or reduced pricing will be available to those students who meet the guidelines.

Renaissance Charter School at Boggy Creek is a part of the National School Lunch Program and free or reduced pricing is available to those students who meet the guidelines.

Maryland Hunger Solutions strongly supports Maryland Meals for Achievement (MMFA), a state - funded program that expands access to universal, free Breakfast in the Classroom in schools where at least 40 % of students are eligible for free and reduced priced meals.

To be eligible, a charter school must have been open in school year 2011 - 12 with at least 50 % of students enrolled in the Free or Reduced - Price Lunch program.

For a district qualifying under this paragraph whose charter school tuition payments exceed 9 per cent of the school district's net school spending, the board shall only approve an application for the establishment of a commonwealth charter school if an applicant, or a provider with which an applicant proposes to contract, has a record of operating at least 1 school or similar program that demonstrates academic success and organizational viability and serves student populations similar to those the proposed school seeks to serve, from the following categories of students, those: (i) eligible for free lunch; (ii) eligible for reduced price lunch; (iii) that require special education; (iv) limited English - proficient of similar language proficiency level as measured by the Massachusetts English Proficiency Assessment examination; (v) sub-proficient, which shall mean students who have scored in the «needs improvement», «warning» or «failing» categories on the mathematics or English language arts exams of the Massachusetts Comprehensive Assessment System for 2 of the past 3 years or as defined by the department using a similar measurement; (vi) who are designated as at risk of dropping out of school based on predictors determined by the department; (vii) who have dropped out of school; or (viii) other at - risk students who should be targeted to eliminate achievement gaps among different groups of students.

Renaissance Charter School at Boggy Creek will participate in the National School Lunch Program and free or reduced pricing will be available to those students who meet the guidelines.

In 2015 - 16, districts were required to cover only $ 15 of the $ 93 exam fee for students who qualify for free or reduced - price meals thanks in part to the U.S. Department of Education's Advanced Placement Test Fee Grant Program, which provided funding for low - income students to take AP exams at a reduced rate.

First there's Amazon, whose Kindle MatchBook program lets you buy ebooks at reduced prices if... Read more»

The Kindle First program gives Kindle First members the opportunity to download one of six editors» picks a month before the official publication date, either for free or at a reduced price.

Through our community spay / neuter voucher program, several hundreds of dogs & cats were altered this past year at reduced prices by our partnered veterinary clinic.

Almost 12 million dogs and cats are euthanized each year because there are not enough homes for them.Local pet owners have a chance to take part in a national program to reduce the number of unwanted animals.As an extension of February's Spay Day USA, several veterinarians and animal hospitals in Seminole and Orange counties still are offering discounted spay and neuter operations in March.For details, prices and appointments, call organizers at [phone].

What happens in the longer term depends on whether pricing signals or spending programs prove more effective at reducing emissions.

In the New England example above, customers opt into a price - based program, receiving a refund at wholesale power prices in exchange for reducing their load during a demand response «event» (a short period of time, determined by the utility or ISO).

However his estimates for carbon payments for Reducing Emissions from Deforestation and Degradation (REDD) program could offset the lost profits from palm oil production, at prices of $ 10 - 33 per tonne of CO2, or $ 2 - 16 per tonne if forest conservation targets only cost - efficient areas.

California's program provides low - income drivers with basic liability coverage mandated by state law at a regulated rate, allowing them to get their cars on the road legally for a reduced price.

Mr. Pichai has created several programs aimed at lowering the price of entry - level smartphones by reducing the cost of the parts within them while still providing a smooth experience.

I think 18 months is too short a time to face the issue, so Apple needs to figure out a way to compensate users either by offering them a free battery replacement program or at least offer the service at reduced prices.

The federal 340B Drug Pricing Program helps participating safety - net centers to obtain prescription drugs at reduced rates from pharmaceutical manufacturers, in turn enabling these sites to more readily absorb the cost of providing contraceptives at little or no cost to their clients.